Hi kin ,
I was referring to the ann late july , re NAL receiving
'unsolicited approaches , in relation to the technology , from a number of sources.'
From what i have experienced the aus market undervalues aus tech, here specifically bio , and the true value is only often seen when a large pharma gobbles one of ours up.